GH Research PLC (GHRS) vs Rapport Therapeutics, Inc. Common Stock (RAPP)

A side-by-side comparison of GH Research PLC and Rapport Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
GH Research PLC logo
GHRS
GH Research PLC
$1.47B
$21.49HealthcareDelayed quote: Oct 6, 2026, 2:05 PM EDT
Rapport Therapeutics, Inc. Common Stock logo
RAPP
Rapport Therapeutics, Inc. Common Stock
$1.46B
$30.50HealthcareDelayed quote: Oct 6, 2026, 2:05 PM EDT

Total return — GHRS vs RAPP

growth of $100 · dividends reinvested · last 2y
GHRS +83.7% (+35.5%/yr)RAPP +54.8% (+24.4%/yr)GHRS compounded faster over this window
50100150200250Start $10020252026$184$155
GHRS RAPP

GHRS vs RAPP: by the numbers

  • •GHRS is the larger company ($1.47B vs $1.46B market cap).
  • •Both run net losses; GHRS's is the smaller (0.00% vs -685.80% net margin).

Metrics side by side

Valuation

MetricGHRSRAPP
P/S ratioN/A72.93
P/B ratio4.103.45

Profitability

MetricGHRSRAPP
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%-685.80%
ROE-17.32%-32.43%
ROIC-19.87%-35.66%

Growth (annualized)

MetricGHRSRAPP
Total return CAGR (5Y)0.52%N/A

Go deeper

Full GHRS analysisFull RAPP analysisInteractive comparison tool

Dig into the metrics

GH Research ROERapport Therapeutics, Inc. Common Stock ROEGH Research operating marginRapport Therapeutics, Inc. Common Stock operating marginGH Research revenue growthRapport Therapeutics, Inc. Common Stock revenue growthGH Research free cash flowRapport Therapeutics, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.